| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
RNS News Service
I confirm that I am accessing this story in my capacity as a private investor and NOT for professional purposes.
Director/PDMR Shareholding
RNS
|
RNS Number : 5383D
GlaxoSmithKline PLC
28 October 2020
GlaxoSmithKline plc
(the '
Company
')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Sir Jonathan Symonds
|
|
b)
|
Position/status
|
Non-Executive Chairman
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2020 to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.50
|
3,240.741
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|
Aggregated volume Price
|
|
|
e)
|
Date of the transaction
|
2020-10-28
|
|
f)
|
Place of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mr Charles Bancroft
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the transaction
|
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2020 to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$35.29
|
866.616
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|
Aggregated volume Price
|
|
|
e)
|
Date of the transaction
|
2020-10-28
|
|
f)
|
Place of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mr Vindi Banga
|
|
b)
|
Position/status
|
Senior Independent Non-Executive Director
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2020 to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.50
|
671.296
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|
Aggregated volume Price
|
|
|
e)
|
Date of the transaction
|
2020-10-28
|
|
f)
|
Place of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Dr Vivienne Cox
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2020 to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.50
|
625.000
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|
Aggregated volume Price
|
|
|
e)
|
Date of the transaction
|
2020-10-28
|
|
f)
|
Place of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Ms Lynn Elsenhans
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the transaction
|
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2020 to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$35.29
|
615.753
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|
Aggregated volume Price
|
|
|
e)
|
Date of the transaction
|
2020-10-28
|
|
f)
|
Place of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Dr Laurie Glimcher
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the transaction
|
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2020 to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$35.29
|
1,140.284
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|
Aggregated volume Price
|
|
|
e)
|
Date of the transaction
|
2020-10-28
|
|
f)
|
Place of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Dr Jesse Goodman
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the transaction
|
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2020 to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$35.29
|
376.294
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|
Aggregated volume Price
|
|
|
e)
|
Date of the transaction
|
2020-10-28
|
|
f)
|
Place of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Ms Judy Lewent
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the transaction
|
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2020 to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$35.29
|
399.099
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|
Aggregated volume Price
|
|
|
e)
|
Date of the transaction
|
2020-10-28
|
|
f)
|
Place of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mr Urs Rohner
|
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2020 to 30 September 2020.
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.50
|
625.000
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|
Aggregated volume Price
|
|
|
e)
|
Date of the transaction
|
2020-10-28
|
|
f)
|
Place of the transaction
|
N/A
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
DSHDVLFLBBLZFBE
|
|
|
|
|
|
